Profile data is unavailable for this security.
About the company
Faes Farma SA is a Spain-based company engaged in the pharmaceutical industry. The Company specializes in the research, production, distribution and sale of prescription and generic drugs, over-the-counter (OTC) medicines, food supplements and personal care treatments, as well as raw materials for the pharmaceutical use. The Company’s research lines are mainly focused on the development of new drugs for the treatment of allergy, venous insufficiency and irritable bowel syndrome, among others. In addition, it provides animal nutrition products. The Company operates in Spain, Portugal, Chile and Mexico, among others. It controls a number of subsidiaries, such as Laboratorios Vitoria SA, Laboratorios Veris SA, Lazlo International SA, Ingaso Farm SLU, Esfion SA and Biotecnet I MAS D SA.
- Revenue in EUR (TTM)568.11m
- Net income in EUR105.08m
- Incorporated1933
- Employees756.00
- LocationFaes Farma SAAvda. Autonomia 10LEIOA 48940SpainESP
- Phone+34 944818300
- Fax+34 944818301
- Websitehttps://faesfarma.com/
More ▼
Mergers & acquisitions
| Acquired company | FAE:MCE since announced | Transaction value |
|---|---|---|
| SIFI SpA | 23.90% | 366.01m |
| Laboratorio Edol Produtos Farmaceuticos Sa | 51.70% | 81.00m |
Data delayed at least 15 minutes, as of Feb 13 2026 16:35 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tibet Rhodiola Pharmaceutical Holding Co | 331.79m | 119.67m | 1.64bn | 596.00 | 13.72 | 3.79 | -- | 4.95 | 3.04 | 3.04 | 8.44 | 11.02 | 0.5188 | 1.38 | 6.52 | 4,564,666.00 | 18.84 | 14.99 | 25.61 | 19.30 | 92.08 | 92.11 | 36.31 | 23.95 | 2.89 | -- | 0.1971 | 52.89 | -10.45 | 17.45 | 31.26 | 27.47 | -5.16 | 27.43 |
| Consun Pharmaceutical Group Ltd | 398.92m | 123.19m | 1.64bn | 3.07k | 13.59 | 3.13 | 12.49 | 4.11 | 1.33 | 1.33 | 4.31 | 5.78 | 0.5642 | 2.35 | 12.33 | 1,169,558.00 | 17.60 | 14.71 | 24.67 | 22.82 | 76.62 | 75.04 | 31.20 | 29.56 | 3.32 | -- | 0.0517 | 40.93 | 14.56 | 11.42 | 16.05 | 62.72 | -9.54 | 25.83 |
| EIS czcbs lc Sn v Fnnsl Ytrmlr Sny v Tcr | 171.55m | 46.99m | 1.67bn | 1.10k | 35.45 | 1.50 | 26.41 | 9.71 | 3.55 | 3.55 | 12.98 | 83.78 | 0.1393 | 3.47 | 5.91 | 8,173,382.00 | 3.81 | 6.40 | 4.07 | 6.86 | 26.87 | 33.31 | 27.39 | 40.47 | 1.87 | -- | 0.0602 | 27.65 | -6.28 | 58.48 | -74.12 | 44.46 | 151.56 | 88.80 |
| Ultragenyx Pharmaceutical Inc | 566.81m | -484.85m | 1.67bn | 1.29k | -- | -- | -- | 2.94 | -5.84 | -5.84 | 6.82 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 83.85 | 88.44 | -85.54 | -122.25 | -- | -12.60 | -- | -- | 20.13 | 19.95 | -1.02 | -- | -- | -- |
| Bora Pharmaceuticals Co Ltd | 533.54m | 123.15m | 1.67bn | 91.00 | 14.37 | 5.36 | 10.77 | 3.14 | 34.10 | 24.33 | 143.28 | 91.50 | 0.4537 | 2.76 | 2.11 | -- | 10.60 | 11.35 | 16.48 | 18.81 | 39.99 | 39.47 | 23.36 | 19.44 | 1.07 | -- | 0.5549 | 37.72 | 35.53 | 65.95 | 29.99 | 66.80 | -0.3363 | 74.57 |
| Fagron NV | -100.00bn | -100.00bn | 1.68bn | 3.99k | -- | 3.03 | -- | -- | -- | -- | -- | 7.51 | -- | -- | -- | -- | -- | 7.72 | -- | 9.52 | -- | 44.06 | -- | 9.75 | 1.39 | -- | 0.457 | 20.58 | 9.20 | 11.36 | 12.99 | 8.84 | 10.69 | 17.32 |
| Perrigo Company PLC | 3.61bn | -24.60m | 1.69bn | 8.38k | -- | 0.45 | 6.61 | 0.4673 | -0.2128 | -0.3764 | 31.00 | 32.31 | 0.4023 | 2.34 | 5.75 | 511,015.60 | -0.2743 | -0.7059 | -0.3124 | -0.8082 | 35.46 | 34.96 | -0.682 | -1.76 | 1.44 | 2.41 | 0.4505 | -- | -6.06 | 2.48 | -3,552.27 | -- | -16.23 | 18.65 |
| FAES Farma SA | 568.11m | 105.08m | 1.69bn | 756.00 | 15.89 | -- | 13.10 | 2.97 | 0.336 | 0.336 | 1.82 | -- | -- | -- | -- | 320,062.00 | -- | 13.17 | -- | 15.13 | 65.15 | 64.65 | 18.49 | 20.72 | -- | 155.55 | -- | -- | 9.42 | 6.67 | 21.17 | 11.73 | 13.09 | -- |
| Tsumura & Co | 1.05bn | 160.08m | 1.71bn | 4.27k | 10.46 | 0.9885 | 7.29 | 1.64 | 387.15 | 387.15 | 2,524.84 | 4,095.99 | 0.374 | 0.7106 | 2.41 | 44,357,680.00 | 6.01 | 5.53 | 8.06 | 6.85 | 47.60 | 49.39 | 16.06 | 14.50 | 1.45 | -- | 0.2856 | 31.65 | 20.05 | 8.00 | 94.10 | 18.69 | 23.07 | 16.27 |
| Shanghai Shyndec Pharmaceutical Co Ltd | 1.13bn | 113.45m | 1.74bn | 11.47k | 15.33 | 1.05 | -- | 1.54 | 0.6936 | 0.6936 | 6.91 | 10.17 | 0.4703 | 2.95 | 7.65 | 807,583.30 | 5.41 | 5.14 | 7.83 | 8.21 | 33.20 | 40.86 | 11.50 | 7.82 | 2.62 | -- | 0.003 | 20.02 | -9.38 | -2.16 | 56.62 | 10.55 | -11.46 | 24.57 |
| Harmony Biosciences Holdings Inc | 695.92m | 156.45m | 1.75bn | 246.00 | 11.34 | 2.48 | 9.90 | 2.51 | 3.18 | 3.18 | 14.13 | 14.50 | 0.7732 | 26.70 | 9.07 | -- | 17.38 | 15.64 | 21.20 | 19.13 | 77.70 | 79.78 | 22.48 | 20.61 | 3.72 | -- | 0.1679 | 0.00 | 22.80 | 160.18 | 12.91 | -- | -56.63 | -- |
Data as of Feb 13 2026. Currency figures normalised to Faes Farma SA's reporting currency: Euro EUR
13.54%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Alantra EQMC Asset Management SGIIC SAas of 31 Dec 2024 | 25.46m | 8.05% |
| Fidelity Management & Research Co. LLCas of 30 Nov 2025 | 4.72m | 1.49% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 4.46m | 1.41% |
| Santander Asset Management SA SGIICas of 31 Dec 2024 | 2.10m | 0.66% |
| KBC Asset Management NVas of 30 Jun 2025 | 1.88m | 0.60% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 1.35m | 0.43% |
| Praude Asset Management Ltd.as of 31 Aug 2025 | 841.48k | 0.27% |
| Mellon Investments Corp.as of 06 Feb 2026 | 793.71k | 0.25% |
| SSgA Funds Management, Inc.as of 05 Feb 2026 | 645.04k | 0.20% |
| Magallanes Value Investors SA SGIICas of 31 Dec 2024 | 558.02k | 0.18% |
More ▼
Data from 31 Aug 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
